Publications


2022

Estimating Distributions of Breast Cancer Onset and Growth in a Swedish Mammography Screening Cohort.

Strandberg R, Czene K, Eriksson M, Hall P, Humphreys K.


Cancer Epidemiol Biomarkers
202203
https://pubmed.ncbi.nlm.nih.gov/35027432/

Risk of heart disease following treatment for breast cancer – results from a population-based cohort study.

Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, Bergh J, Bian W, Ludvigsson JF, Hall P, Czene K.


Elife
202203
https://pubmed.ncbi.nlm.nih.gov/35293856/

Interval breast cancer is associated with interferon immune response.

Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Lindström LS, Vallon-Christersson J, Borg Å, Hall P, Czene K.


Eur J Cancer
202202
https://pubmed.ncbi.nlm.nih.gov/35026490/

Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.

Thomas CE, Dahl L, Byström S, Chen Y, Uhlén M, Mälarstig A, Czene K, Hall P, Schwenk JM, Gabrielson M.


Transl Oncol
202201
https://pubmed.ncbi.nlm.nih.gov/35033985/

2021

[It is time for individual breast cancer prevention].

Hall P, Hammarström M, Hellgren R.


Läkartidningen
202109
https://pubmed.ncbi.nlm.nih.gov/34498240/

Mammographic features are associated with cardiometabolic disease risk and mortality.

Grassmann F, Yang H, Eriksson M, Azam S, Hall P, Czene K.


Eur Heart J
202109
https://pubmed.ncbi.nlm.nih.gov/34338750/

Mammographic microcalcifications and risk of breast cancer.

Azam S, Eriksson M, Sjölander A, Gabrielson M, Hellgren R, Czene K, Hall P.


Br J Cancer
202108
https://pubmed.ncbi.nlm.nih.gov/34127810/

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial

W He, M Eriksson, E Eliasson, F Grassmann, M Bäcklund, M Gabrielson, M Hammarström, S Margolin, L Thorén, Y Wengström, S Borgquist, P Hall, K Czene.


Annals of Oncology
202107
https://pubmed.ncbi.nlm.nih.gov/34284099/

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, Rosendahl A, Lång K, Tapia J, Bäcklund M, Discacciati A, Crippa A, Gabrielson M, Hammarström M, Wengström Y, Czene K, Hall P.


J Clin Oncol.
202103
https://pubmed.ncbi.nlm.nih.gov/33734864

Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.

Ong JS, Derks EM, Eriksson M, An J, Hwang LD, Easton DF, Pharoah PP, Berchuck A, Kelemen LE, Matsuo K, Chenevix-Trench G, Hall P, Bojesen SE, Webb PM, MacGregor S.


Int J Cancer
202103
https://pubmed.ncbi.nlm.nih.gov/32976626/

Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women.

Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, et al.


N Engl J Med.
202101
https://pubmed.ncbi.nlm.nih.gov/33471991

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.

Eriksson M, Czene K, Conant EF, Hall P.


Cancers (Basel).
202101
https://pubmed.ncbi.nlm.nih.gov/33467653

2020

Sense of coherence and risk of breast cancer.

Hu K, Eriksson M, Wengström Y, Czene K, Hall P, Fang F.


Elife.
202011
https://pubmed.ncbi.nlm.nih.gov/33226344

Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.

Holm J, Yu NY, Johansson A, Ploner A, Hall P, Lindström LS, Czene K.


JNCI Cancer Spect
202010
https://pubmed.ncbi.nlm.nih.gov/33442660/

Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study.

Tan PS, Ali MA, Eriksson M, Hall P, Humphreys K, Czene K.


Int J Cancer.
202009
https://pubmed.ncbi.nlm.nih.gov/32976625

Predictors of mammographic microcalcifications.

Azam S, Eriksson M, Sjölander A, Gabrielson M, Hellgren R, Czene K, Hall P.


Int J Cancer.
202009
https://pubmed.ncbi.nlm.nih.gov/32949149

Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.

Eriksson M, Czene K, Strand F, Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D, Hall P.


Radiology.
202009
https://pubmed.ncbi.nlm.nih.gov/32897160

Association between breast cancer risk and disease aggressiveness: characterizing underlying gene expression patterns.

Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Borg Å, Vallon-Christersson J, Hall P, Czene K.


Int J Cancer.
202008
https://pubmed.ncbi.nlm.nih.gov/32856720

Hormonal determinants of mammographic density and density change.

Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, Bäcklund M, Bergquist J, Czene K, Hall P.


Breast Cancer Res.
202008
https://pubmed.ncbi.nlm.nih.gov/32847607

Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors.

Yang H, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K.


BMC Med.
202008
https://pubmed.ncbi.nlm.nih.gov/32838791/